Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Research Report 2022

As for March 26, 2020

1.BCG Vaccine Clinical Experiment for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.
The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.

2.Introduce of VPM1002，a Genetically Modified More Effective BCG Vaccine
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.
The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.
Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.

3.Research Progress for VPM1002
Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.
The vaccine is currently being tested in a further Phase III study on adult volunteers in India.
Due to the COVID-19 pandemic, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
0.5ml Package accounting for % of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While 0-5 Years Old segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 include Vakzine Projekt Management (VPM) and Serum Institute of India etc. In terms of revenue, the global 3 largest players have a % market share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in 2021.
This report focuses on VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Vakzine Projekt Management (VPM)
Serum Institute of India

Frequently Asked Questions